[Hormone therapy, cardio-metabolic profile and cardiotoxicity. Still a dark side of cardio-oncology. Part 1: Breast cancer]. / Terapia ormonale, assetto cardio-metabolico e cardiotossicità. Il lato ancora oscuro della cardioncologia Parte 1: Cancro della mammella.
G Ital Cardiol (Rome)
; 23(4): 286-294, 2022 Apr.
Article
in It
| MEDLINE
| ID: mdl-35343480
ABSTRACT
Hormone therapy with anti-estrogenic purposes is a cornerstone in breast cancer therapy that expresses estrogen receptors, the most frequent immunohistotype among invasive breast cancer. Hormone therapy is administered for a long time and affects the cardio-metabolic profile with possible interactions with the woman's intrinsic cardiovascular risk and the cardiotoxic effects of other treatments (chemotherapy, radiotherapy, target therapy). In this review, we analyze the pathophysiological implications and cardiovascular effects of hormone therapy providing useful elements for the creation of a personalized management program based on the "stepwise approach" as recommended by the 2021 cardiovascular disease prevention guidelines of the European Society of Cardiology and on the possible use of new antidiabetic drugs potentially useful for the management of the metabolic syndrome.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Antineoplastic Agents
Type of study:
Etiology_studies
/
Guideline
Limits:
Female
/
Humans
Language:
It
Journal:
G Ital Cardiol (Rome)
Journal subject:
CARDIOLOGIA
Year:
2022
Document type:
Article
Publication country:
IT
/
ITALIA
/
ITALY
/
ITÁLIA